Takeda

Takeda is a Japan-based global biopharmaceutical company with a major research and business hub in Cambridge, where it is one of the largest employers in the region’s biotech sector. The company focuses on discovering and delivering medicines for patients with serious and often underserved conditions, working across oncology, rare genetic and blood disorders, neuroscience, gastrointestinal and inflammatory diseases, and plasma-derived therapies. Its pipeline includes potential first-in-class treatments that target the underlying causes of disease.

The company’s history stretches back more than 240 years to a medicine business in Osaka, Japan, making it one of the oldest pharmaceutical companies in the world. Over the past two decades it has expanded its Greater Boston presence through acquisitions, building a large workforce of researchers and specialists in the area. Takeda frames its work around a promise to reinvent for a healthier world, and it invests in corporate social responsibility programs, including global collaborations on climate-ready health care chosen by its employees.

What to Know

• Takeda’s recent approvals include treatments for narcolepsy type 1 and polycythemia vera.
• Its late-stage pipeline includes zasocitinib, an oral once-daily pill for plaque psoriasis.
• The company shares financial results through an investor newsletter.
• Takeda is a member of the Greater Boston Chamber of Commerce.